Funding Announcements

"This collaboration marks the beginning of an exciting new chapter for us, especially as we expand into the Japanese and Asia markets. Hamamatsu’s support has also been invaluable in our recently established U.S. operation, where their network has been helping us establish critical connections to scale our business."

"Backing Bioniq goes beyond just an investment opportunity for me—it’s about aligning with a shared vision for health, performance, and longevity. I have been using their products myself for almost three years. With their personalized health approach, I believe Bioniq has the potential to transform how we care for our bodies and help people reach and maintain their peak performance for longer."

"This significant investment demonstrates continued confidence in our team, our eProtein Discovery system, and our potential to revolutionize the way proteins are made. This funding will accelerate our mission to provide ready-to-use benchtop protein screening and making tools to empower protein scientists around the world. We are excited to enhance our support for our customers, enabling them to make proteins for drug discovery more efficiently and effectively for many years to come."

"A third of all FDA-approved drugs target GPCRs, yet, despite decades of research and billions of funding, only a few GPCR-targeting antibodies exist. Thanks to the support of our investors, we are one step closer to making GPCRs and other challenging targets druggable, bringing needed therapies to patients across the globe."

"We are excited to welcome BGF as a strategic partner. Their investment will enable us to scale our operations, enhance our product offerings and reach new markets. This partnership is a testament to the strength of our business model and the potential for future growth. We are confident that with BGF’s support, and the highly relevant experience of Gareth Miller, we will continue to lead the way in delivering cutting-edge healthcare technology market intelligence solutions."